• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ann Vasc Dis . Prediction of Functional Outcomes at Discharge Using Plasma Concentration of von Willebrand Factor Antigen at Admission in Hospitaliz

tetano

tetano

Editor, Senior Moderator
Ann Vasc Dis


. 2026;19(1):25-00153.
doi: 10.3400/avd.oa.25-00153. Epub 2026 Feb 5.
Prediction of Functional Outcomes at Discharge Using Plasma Concentration of von Willebrand Factor Antigen at Admission in Hospitalized Patients with COVID-19​

Masayuki Oki[SUP] 1 [/SUP], Daisuke Yamasawa[SUP] 1 [/SUP], Shinichi Goto[SUP] 1 [/SUP], Hidetaka Yanagi[SUP] 1 [/SUP], Saki Manabe[SUP] 1 [/SUP], Takako Kobayashi[SUP] 1 [/SUP], Ayumi Tsuda[SUP] 1 [/SUP], Shota Sato[SUP] 1 [/SUP], Seiji Morita[SUP] 2 [/SUP], Yoshihide Nakagawa[SUP] 2 [/SUP], Tsuyoshi Oguma[SUP] 3 [/SUP], Koichiro Asano[SUP] 3 [/SUP], Norio Yamamoto[SUP] 4 [/SUP], Hideki Ozawa[SUP] 1 [/SUP], Shinya Goto[SUP] 5 [/SUP]


Affiliations
Abstract

Objectives: Coronavirus disease 2019 (COVID-19) causes endothelial injury through inflammatory and hypoxic stress, leading to vascular dysfunction and immunothrombosis. The plasma level of von Willebrand factor (VWF) could serve as a biomarker of vascular injury. While elevated VWF predicts mortality in severe COVID-19, its relationship with post-discharge functional outcomes remains unclear. This study aimed to determine whether plasma VWF antigen (VWF:Ag) levels at admission predict functional status at discharge in patients hospitalized for COVID-19.
Methods: This was a single-center prospective cohort study conducted at Tokai University Hospital from July to September 2021. We evaluated the relationship between plasma VWF:Ag levels at admission and a Clinical Frailty Scale (CFS) score ≥4 at discharge using univariable and multivariable logistic regression analyses.
Results: A total of 97 patients were enrolled in the study. The median VWF:Ag level at admission was 330.0% (95% confidence interval [CI]: 273.0-391.8). Univariable analysis showed a significant association between elevated VWF:Ag levels and CFS score ≥4 at discharge. This association remained significant after adjusting for age and sex (odds ratio 1.010, 95% CI: 1.000-1.010, p = 0.005).
Conclusion: Elevated VWF:Ag levels at admission predict poor functional outcomes at discharge in COVID-19 patients, independent of age and sex.

Keywords: ADAMTS13; COVID-19; endothelial injury; functional outcome; von Willebrand factor.

​
 
You must log in or register to reply here.
Back
Top Bottom